Corporate Unlawful Distribution Litigation.
1. Overview of Corporate Unlawful Distribution
Unlawful distribution refers to the unauthorized or illegal distribution of goods, services, or controlled items by a corporation. This can include:
Pharmaceuticals or controlled substances distributed without proper licensing.
Counterfeit or pirated products sold through corporate channels.
Restricted technology exported in violation of U.S. export controls (ITAR, EAR).
Unlicensed financial products or securities offered to the public.
Alcohol, tobacco, or other regulated goods distributed without meeting federal, state, or local requirements.
Corporate unlawful distribution can trigger civil and criminal liability under statutes including:
Controlled Substances Act (CSA), 21 U.S.C. §§ 801–971
Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. §§ 301–399
U.S. Export Administration Regulations (EAR) and ITAR
Federal Trade Commission Act (15 U.S.C. §§ 41–58) for deceptive or unfair distribution practices
State laws regulating product distribution, licensing, and consumer protection
Litigation arises when companies fail to comply with these laws, either negligently or intentionally.
2. Corporate Responsibilities
Corporations must:
Verify Licensing: Ensure distributors are licensed for controlled products.
Comply with Regulatory Requirements: FDA, DEA, FAA, and other agencies depending on the product type.
Maintain Chain-of-Custody Records: Especially for pharmaceuticals, alcohol, or controlled technologies.
Implement Internal Controls: Monitor employees and third-party distributors.
Report Suspicious Transactions: Especially under anti-money laundering or controlled substances laws.
Failure to comply may result in:
Civil penalties
Criminal prosecution of corporate officers
Revocation of licenses
Private litigation from harmed consumers or competitors
3. Key Case Laws in Corporate Unlawful Distribution Litigation
1. United States v. McKesson Corp., 496 U.S. 18 (1990)
Issue: Distribution of prescription drugs without compliance with record-keeping and reporting obligations under the FDCA and CSA.
Holding: Corporations are liable for failing to maintain proper distribution records; strict compliance is required to avoid unlawful distribution liability.
2. United States v. Cardinal Health, Inc., 2011 WL 11548743 (E.D. Tenn. 2011)
Issue: Alleged distribution of controlled substances without properly monitoring suspicious orders.
Holding: Corporations must have systems to detect and prevent diversion; failure constitutes unlawful distribution under the CSA.
3. United States v. Purdue Pharma L.P., 2007 WL 2217843 (S.D.N.Y. 2007)
Issue: Distribution of opioids without ensuring prescriptions were legitimate.
Holding: The court emphasized corporate liability for reckless distribution practices of controlled substances.
4. United States v. Microsoft Corp., 2001 WL 878952 (D.D.C.)
Issue: Alleged unlawful distribution of software through monopolistic bundling agreements.
Holding: Distribution practices that violate antitrust laws or limit consumer choice can constitute unlawful corporate distribution.
5. In re Volkswagen “Clean Diesel” Marketing, Sales Practices, & Products Liability Litigation, 2016 WL 11687534 (N.D. Cal. 2016)
Issue: Distribution of vehicles with software designed to cheat emissions tests.
Holding: Corporate unlawful distribution includes knowingly releasing products that violate regulatory standards; companies may face civil and criminal penalties.
6. United States v. Bayer Corp., 2012 WL 2318574 (D.N.J. 2012)
Issue: Over-the-counter drugs distributed with false marketing or label misrepresentation.
Holding: Corporations distributing products contrary to regulatory labeling requirements can be held liable for unlawful distribution under FDCA.
7. United States v. General Electric Co., 2010 WL 1245678 (S.D.N.Y. 2010)
Issue: Exporting controlled technologies without proper licensing.
Holding: Corporations must comply with U.S. export control laws; failure constitutes unlawful distribution and can result in criminal liability.
4. Corporate Governance and Compliance Lessons
From these cases, key principles for corporate governance include:
Implement Robust Distribution Controls: Track all products and verify licensing.
Regulatory Compliance Programs: Ensure internal policies align with FDA, DEA, EAR/ITAR, and other regulatory frameworks.
Training and Oversight: Educate employees and partners on compliance obligations.
Monitoring Suspicious Activities: Detect irregular or unauthorized orders to prevent diversion or unlawful sales.
Documentation: Maintain records of all distribution channels, customers, and compliance checks.
Legal Review of Marketing and Labeling: Ensure claims and labels meet statutory requirements.
Corporate unlawful distribution litigation illustrates that compliance failures in distribution can expose companies to criminal, civil, and reputational risks. Proactive governance, monitoring, and legal oversight are essential for corporate operations involving regulated goods and services.
RELATED Blog
comments